Soluble Receptor Level of Advanced Glycation (sRAGE) Products in Serum in Patients with Systemic Lupus Erythematosus:
- 22 July 2024
- journal article
- research article
- Published by Kahramanmaras Sutcu Imam Universitesi Tip Fakultesi Dergisi in Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi
- Vol. 19 (2) , 29-34
Abstract
Objectives: Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by antibody formation against nuclear autoantigens. A receptor for Advanced Glycation (RAGE) is produced by many immune system cells, such as neutrophils, macrophages, and T cells, and interacts with many classes of ligands. In light of these results, the level of sRAGE, the soluble form of RAGE, may be associated with disease activity. In light of this information, we aimed to evaluate whether there is a relationship between plasma sRAGE levels and SLE. Materials and Methods: Eighteen patients diagnosed with SLE (M/F: 1/17) and twenty-one patients without any disease diagnosis (M/F: 2/19) were included as the control group. In these patients, plasma sRAGE level was measured by ELIZA method using an ELIZA (enzyme-linked immunosorbent assay) kit (BioVendor Research and Diagnostic Products). The data obtained were compared between the groups. Results: The mean plasma sRAGE level was lower in patients with SLE than in healthy control patients but not statistically significant (p=0.966). Our study found a positive correlation between SLEDAI and sRAGE levels in patients with SLE (r=0.628, p=0.005). Although no significant correlation was found between patients with SLE, sRAGE levels were positively correlated between fourteen patients classified as active SLE and the control group. Conclusions: In our study, we found that plasma sRAGE levels in patients with SLE were lower than in healthy controls, but plasma sRAGE levels in patients with active SLE were higher than plasma sRAGE levels in patients with inactive SLE. We hypothesized that reduced sRAGE levels in patients with SLE could be explained by the depletion of this soluble receptor. Our study differed from another similar study showing that blood sRAGE levels were higher in patients with SLE than in healthy controls. Blood sRAGE levels were significantly increased during active disease compared with patients with quiescent SLE.Keywords
This publication has 30 references indexed in Scilit:
- Methylglyoxal modified IgG generates autoimmune response in rheumatoid arthritisInternational Journal of Biological Macromolecules, 2018
- Advanced glycation endproducts and their receptor RAGE in Alzheimer's diseaseNeurobiology of Aging, 2011
- Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-alpha and TNF-alpha in systemic lupus erythematosusRheumatology International, 2010
- HMGB1 in systemic lupus Erythematosus: Its role in cutaneous lesions developmentAutoimmunity Reviews, 2010
- Decreased levels of soluble receptor for advanced glycation end products in patients with primary Sjögren’s syndromeRheumatology International, 2008
- Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetesDiabetologia, 2006
- Proinflammatory S100 proteins in arthritis and autoimmune diseaseArthritis & Rheumatism, 2004
- S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional rolesThe International Journal of Biochemistry & Cell Biology, 2001
- Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritisArthritis & Rheumatism, 2000
- Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injuryDiabetologia, 1997